MedTrace Logo

The Effect of Proprioception of Platelet Rich Plasma for Patients With Ankle Sprain

NCT03808454 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-10-02

No results posted yet for this study

Summary

Ankle sprain is a fairly common sports medicine clinic. In Taiwan at least 150,000 to 200,000 people will suffer from ankle sprains every years. Clinicians have been looking for ways to shorten treatment time and reduce discomfort. Platelet Rich Plasma(PRP) is an endogenous therapeutic technology that involved in regenerative medicine due to its potential to stimulate and accelerate tissue healing. PRP can release lots of growth factors like platelet-derived growth factor (PDGF),transforming Growth Factor Beta(TGF-β), vascular endothelial growth factor(VEGF),Epidermal growth factor(EGF) and insulin-like growth factor (IGF). Its use had been based on the theory that increased autologous platelets, that then yield high concentrations of growth factors and other proteins, will lead to increased healing of tendon and soft tissue on a cellular level. In addition, there is no objective evaluation after treatment, so that patients can not provide effective and accurate quantitative feedback. In this study, the investigators divided patients into three groups, respectively, general rehabilitation therapy, autologous PRP injection therapy, autologous PRP injection combined with general rehabilitation therapy.

Conditions

  • Ankle Sprain 2Nd Degree
  • Ankle Sprain 3Rd Degree

Interventions

DRUG

PRP

The investigators draw 10cc of blood and concentrate the blood to get the platelet rich plasma

OTHER

Rehabilitation

strengthening ex, posture training,...

COMBINATION_PRODUCT

PRP+Rehabilitation

combine PRP and Rehabilitation

Sponsors & Collaborators

  • Tri-Service General Hospital

    collaborator OTHER

  • National Defense Medical Center, Taiwan

    lead OTHER

Principal Investigators

  • Shang-Lin Chiang, PhD · Department of rehabiliation,TSGH, Taipei, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03808454 on ClinicalTrials.gov